Clinical Trials Browser

Phase 1/2 × Neuroendocrine Tumors × pembrolizumab × Clear all

NCT03910660 2025-10-20

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Phase 1/2 Completed

EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors